References
1. Vanoli F, Mantegazza R. Ravulizumab for the treatment of myasthenia
gravis. Expert Opin Biol Ther . 2023;23(3):235-241.
doi:10.1080/14712598.2023.21851312. Meisel A, Annane D, Vu T, et al.
Long-term efficacy and safety of ravulizumab in adults with
anti-acetylcholine receptor antibody-positive generalized myasthenia
gravis: results from the phase 3 CHAMPION MG open-label extension.J Neurol . 2023;270(8):3862-3875. doi:10.1007/s00415-023-11699-x3.
Vu T, Wiendl H, Katsuno M, Reddel S, Howard Jr J. Ravulizumab in
Myasthenia Gravis: A Review of the Current Evidence. NDT .
2023;Volume 19:2639-2655. doi:10.2147/NDT.S3746944. Howard JF,
Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in
anti-acetylcholine receptor antibody-positive refractory generalised
myasthenia gravis (REGAIN): a phase 3, randomised, double-blind,
placebo-controlled, multicentre study. Lancet Neurol .
2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-15. Vu T, Meisel A,
Mantegazza R, et al. Terminal complement inhibitor ravulizumab in
generalized myasthenia gravis. NEJM Evid . 2022;1(5).
doi:10.1056/EVIDoa21000666. Muppidi S, Utsugisawa K, Benatar M, et al.
Long‐term safety and efficacy of eculizumab in generalized myasthenia
gravis. Muscle Nerve . 2019;60(1):14-24. doi:10.1002/mus.264477.
Vinciguerra C, Bevilacqua L, Toriello A, et al. Starting eculizumab as
rescue therapy in refractory myasthenic crisis. Neurol Sci .
2023;44(10):3707-3709. doi:10.1007/s10072-023-06900-y8. Uzawa A, Ozawa
Y, Yasuda M, Kuwabara S. Severe worsening of myasthenic symptoms after
the eculizumab discontinuation. J Neuroimmunol . 2020;349:577424.
doi:10.1016/j.jneuroim.2020.5774249. Tokuyasu D, Suzuki S, Uzawa A, et
al. Real‐world experience with eculizumab and switching to ravulizumab
for generalized myasthenia gravis. Ann Clin Transl Neurol .
2024;11(5):1338-1346. doi:10.1002/acn3.52051